RADIATION MITIGATOR AND METHOD OF USE THEREOF
Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.
1 . A method for treating or preventing radiation-induced tissue injury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by formula I
or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—, thereby treating or preventing radiation-induced tissue injury in the subject.
2 . The method of claim 1 , wherein Z is —O—.
3 . The method of claim 1 , wherein Z is —N(H)—.
4 . The method of claim 1 , wherein the compound is administered prior to exposure of the subject to radiation.
5 . The method of claim 1 , wherein the compound is administered after exposure of the subject to radiation.
6 . The method of any one of claims 1-5 , wherein the radiation-induced tissue injury is acute radiation-induced tissue injury.
7 . The method of any one of claims 1-5 , wherein the radiation-induced tissue injury is chronic radiation-induced tissue injury.
8 . The method of any one of claims 1-7 , wherein the tissue comprises gastrointestinal tissue.
9 . The method of any one of claims 1-7 , wherein the tissue comprises hematopoietic tissue.
10 . The method of any one of claims 1-7 , wherein the tissue comprises neural tissue.
11 . The method of any one of claims 1-10 , wherein the compound is administered orally.
12 . The method of any one of claims 1-10 , wherein the compound is administered parenterally.
13 . A method for treating or preventing radiation-induced tissue injury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by formula II
or a pharmaceutically acceptable salt thereof, thereby treating or preventing radiation-induced tissue injury in the subject.
14 . The method of claim 13 , wherein the compound is administered prior to exposure of the subject to radiation.
15 . The method of claim 13 , wherein the compound is administered after exposure of the subject to radiation.
16 . The method of any one of claims 13-15 , wherein the radiation-induced tissue injury is acute radiation-induced tissue injury.
17 . The method of any one of claims 13-15 , wherein the radiation-induced tissue injury is chronic radiation-induced tissue injury.
18 . The method of any one of claims 13-17 , wherein the tissue comprises gastrointestinal tissue.
19 . The method of any one of claims 13-17 , wherein the tissue comprises hematopoietic tissue.
20 . The method of any one of claims 13-17 , wherein the tissue comprises neural tissue.
21 . The method of any one of claims 13-20 , wherein the compound is administered orally.
22 . The method of any one of claims 13-20 , wherein the compound is administered parenterally.
23 . A method for treating or preventing radiation-induced tissue injury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by formula III
or a pharmaceutically acceptable salt thereof, thereby treating or preventing radiation-induced tissue injury in the subject.
24 . The method of claim 23 , wherein the compound is administered prior to exposure of the subject to radiation.
25 . The method of claim 23 , wherein the compound is administered after exposure of the subject to radiation.
26 . The method of any one of claims 23-25 , wherein the radiation-induced tissue injury is acute radiation-induced tissue injury.
27 . The method of any one of claims 23-25 , wherein the radiation-induced tissue injury is chronic radiation-induced tissue injury.
28 . The method of any one of claims 23-27 , wherein the tissue comprises gastrointestinal tissue.
29 . The method of any one of claims 23-27 , wherein the tissue comprises hematopoietic tissue.
30 . The method of any one of claims 23-27 , wherein the tissue comprises neural tissue.
31 . The method of any one of claims 23-30 , wherein the compound is administered orally.
32 . The method of any one of claims 23-30 , wherein the compound is administered parenterally.
33 . A method for treating or preventing radiation-induced tissue injury, comprising co-administering to a subject in need thereof a therapeutically effective amount of a compound represented by formula II
or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a compound represented by formula III
or a pharmaceutically acceptable salt thereof, thereby treating or preventing radiation-induced tissue injury in the subject.
34 . The method of claim 33 , wherein the compounds are co-administered prior to exposure of the subject to radiation.
35 . The method of claim 33 , wherein the compounds are co-administered after exposure of the subject to radiation.
36 . The method of any one of claims 33-35 , wherein the radiation-induced tissue injury is acute radiation-induced tissue injury.
37 . The method of any one of claims 33-35 , wherein the radiation-induced tissue injury is chronic radiation-induced tissue injury.
38 . The method of any one of claims 33-37 , wherein the tissue comprises gastrointestinal tissue.
39 . The method of any one of claims 33-37 , wherein the tissue comprises hematopoietic tissue.
40 . The method of any one of claims 33-37 , wherein the tissue comprises neural tissue.
41 . The method of any one of claims 33-40 , wherein the compounds are co-administered orally.
42 . The method of any one of claims 33-40 , wherein the compounds are co-administered parenterally.
43 . The method of any one of claims 1-42 , wherein the subject is a mammal.
44 . The method of any one of claims 1-43 , wherein the subject is a human.
45 . The method of any one of claims 1-44 , wherein the radiation-induced tissue injury is prevented.
46 . The method of any one of claims 1-44 , wherein the radiation-induced tissue injury is treated.